» Articles » PMID: 29230219

Functional Impairment of Mononuclear Phagocyte System by the Human Respiratory Syncytial Virus

Overview
Journal Front Immunol
Date 2017 Dec 13
PMID 29230219
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The mononuclear phagocyte system (MPS) comprises of monocytes, macrophages (MΦ), and dendritic cells (DCs). MPS is part of the first line of immune defense against a wide range of pathogens, including viruses, such as the human respiratory syncytial virus (hRSV). The hRSV is an enveloped virus that belongs to the family, genus. This virus is the main etiological agent causing severe acute lower respiratory tract infection, especially in infants, children and the elderly. Human RSV can cause bronchiolitis and pneumonia and it has also been implicated in the development of recurrent wheezing and asthma. Monocytes, MΦ, and DCs significantly contribute to acute inflammation during hRSV-induced bronchiolitis and asthma exacerbation. Furthermore, these cells seem to be an important component for the association between hRSV and reactive airway disease. After hRSV infection, the first cells encountered by the virus are respiratory epithelial cells, alveolar macrophages (AMs), DCs, and monocytes in the airways. Because AMs constitute the predominant cell population at the alveolar space in healthy subjects, these cells work as major innate sentinels for the recognition of pathogens. Although adaptive immunity is crucial for viral clearance, AMs are required for the early immune response against hRSV, promoting viral clearance and controlling immunopathology. Furthermore, exposure to hRSV may affect the phagocytic and microbicidal capacity of monocytes and MΦs against other infectious agents. Finally, different studies have addressed the roles of different DC subsets during infection by hRSV. In this review article, we discuss the role of the lung MPS during hRSV infection and their involvement in the development of bronchiolitis.

Citing Articles

Infection of nonclassic monocytes by respiratory syncytial virus induces an imbalance in the CD4 T-cell subset response.

Han L, Li D, Wang C, Ren L, Guo L, Wang J Microbiol Spectr. 2024; 13(1):e0207324.

PMID: 39656009 PMC: 11705840. DOI: 10.1128/spectrum.02073-24.


Modulation of the Gut-Lung Axis by Water Kefir and Kefiran and Their Impact on Toll-like Receptor 3-Mediated Respiratory Immunity.

Dentice Maidana S, Arganaraz Aybar J, Albarracin L, Imamura Y, Arellano-Arriagada L, Namai F Biomolecules. 2024; 14(11).

PMID: 39595633 PMC: 11591811. DOI: 10.3390/biom14111457.


Liposomal Glutathione Augments Immune Defenses against Respiratory Syncytial Virus in Neonatal Mice Exposed in Utero to Ethanol.

Gauthier T, Ping X, Harris F, Brown L Antioxidants (Basel). 2024; 13(2).

PMID: 38397736 PMC: 10886408. DOI: 10.3390/antiox13020137.


Identification of dendritic cell precursor from the CD11c cells expressing high levels of MHC class II molecules in the culture of bone marrow with FLT3 ligand.

In H, Park J, Shin H, Ryu S, Sohn M, Choi W Front Immunol. 2023; 14:1179981.

PMID: 38094300 PMC: 10716454. DOI: 10.3389/fimmu.2023.1179981.


Immunobiotic FFIG58 Confers Long-Term Protection against .

Elean M, Tonetti F, Fukuyama K, Arellano-Arriagada L, Namai F, Suda Y Int J Mol Sci. 2023; 24(21).

PMID: 37958756 PMC: 10648150. DOI: 10.3390/ijms242115773.


References
1.
Reed J, Brewah Y, Delaney T, Welliver T, Burwell T, Benjamin E . Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis. J Infect Dis. 2008; 198(12):1783-93. DOI: 10.1086/593173. View

2.
Cherrie A, Anderson K, Wertz G, Openshaw P . Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. J Virol. 1992; 66(4):2102-10. PMC: 289001. DOI: 10.1128/JVI.66.4.2102-2110.1992. View

3.
Kallal L, Schaller M, Lindell D, Lira S, Lukacs N . CCL20/CCR6 blockade enhances immunity to RSV by impairing recruitment of DC. Eur J Immunol. 2010; 40(4):1042-52. PMC: 2952176. DOI: 10.1002/eji.200939778. View

4.
Paramore L, Ciuryla V, Ciesla G, Liu L . Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics. 2004; 22(5):275-84. DOI: 10.2165/00019053-200422050-00001. View

5.
Kim K, Lee Y, Hwang H, Kwon Y, Kim M, Ko E . Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells. J Virol. 2015; 89(22):11692-705. PMC: 4645681. DOI: 10.1128/JVI.02018-15. View